| 1: Am J
Clin Oncol. 2006 Jun;29(3):320-1. |
|
-
Malignant meningioma in a 3-year-old girl.
Bayram I, Kiymaz N, Harman M, Ugra S.
Department of Pathology, Yil University Faculty of Medicine, Van, Turkey.
bayramirfan@yahoo.co.uk
PMID: 16755189 [PubMed - in process]
-
| 2: Cancer Res. 2006 Apr
15;66(8):4478-87. |
|
-
Adoptive transfer of type 1 CTL mediates effective
anti-central nervous system tumor response: critical roles of IFN-inducible
protein-10.
Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto
A, Storkus WJ, Okada H.
Department of Neurological Surgery, University of Pittsburgh Cancer
Institute, Pennsylvania 15213, USA.
The development of effective immunotherapeutic strategies for central
nervous system (CNS) tumors requires a firm understanding of factors
regulating the trafficking of tumor antigen-specific CTLs into CNS tumor
lesions. Using C57BL/6 mice bearing intracranial (i.c.)
ovalbumin-transfected melanoma (M05), we evaluated the efficacy and tumor
homing of i.v. transferred type 1 or 2 CTLs (Tc1 or Tc2, respectively)
prepared from ovalbumin-specific T-cell receptor-transgenic OT-1 mice. We
also tested our hypothesis that intratumoral (i.t.) delivery of dendritic
cells that had been transduced with IFN-alpha cDNA (DC-IFN-alpha) would
enhance the tumor-homing and antitumor effectiveness of adoptively
transferred Tc1 via induction of an IFN-gamma-inducible protein 10 (IP-10).
In vitro, DC-IFN-alpha induced IP-10 production by M05 and enhanced the
cytolytic activity of Tc1. In vivo, i.v. transferred Tc1 trafficked
efficiently into i.c. M05 and mediated antitumor responses more effectively
than Tc2, and their effect was IP-10 dependent. I.t. injections of DC-IFN-alpha
remarkably enhanced the tumor homing, therapeutic efficacy, and in situ IFN-gamma
production of i.v. delivered Tc1, resulting in the long-term survival and
persistence of systemic ovalbumin-specific immunity. These data suggest that
Tc1-based adoptive transfer therapy may represent an effective modality for
CNS tumors, particularly when combined with strategies that promote a type 1
polarized tumor microenvironment.
PMID: 16618775 [PubMed - indexed for MEDLINE]
-
| 3: Cancer Res. 2006 Apr
15;66(8):4167-72. |
|
-
Hemangioblastomas share protein expression with embryonal
hemangioblast progenitor cell.
Glasker S, Li J, Xia JB, Okamoto H, Zeng W,
Lonser RR, Zhuang Z, Oldfield EH, Vortmeyer AO.
Surgical Neurology Branch, National Institutes of Neurological Disorders and
Stroke, NIH, Bethesda, Maryland 20892, USA.
Hemangioblastomas are central nervous system (CNS) tumors of unknown
histogenesis, which can occur sporadically or in von Hippel-Lindau disease.
Hemangioblastomas are composed of neoplastic "stromal" cells of
unknown origin, accompanied by intensive reactive angiogenesis. Failure to
specify the cytologic origin of the stromal cell has precluded the
development of nonsurgical therapies and limits understanding of its basic
biology. We report that the stromal cells express proteins (Scl, brachyury,
Csf-1R, Gata-1, Flk-1, and Tie-2) that characterize embryonic progenitor
cells with hemangioblastic differentiation potential and conclude that
embryonic progenitors with hemangioblast potential represent a possible
cytologic equivalent of the stromal cell. We also identified a new autocrine/paracrine
stimulatory loop between the receptor Tie-2 and the hypoxia-inducible factor
target Ang-1, which, combined with previous observations, suggests that a
variety of autocrine loops may be initiated in hemangioblastomas, depending
on the differentiation status of the tumor cells and the extent of HIF
downstream activation. Finally, the consistent identification of Scl in the
stromal cells may help explain the unique and characteristic topographical
distribution of hemangioblastomas within the CNS.
PMID: 16618738 [PubMed - indexed for MEDLINE]
 Abstract
| 4: Int
J Radiat Oncol Biol Phys. 2006 May 31; [Epub ahead of print] |
|
-
Boron neutron capture therapy using mixed epithermal and
thermal neutron beams in patients with malignant glioma-correlation between
radiation dose and radiation injury and clinical outcome.
Kageji T, Nagahiro S, Mizobuchi Y, Toi H, Nakagawa
Y, Kumada H.
Department of Neurosurgery, Graduate School of Health Biosciences, The
University of Tokushima, Tokushima, Japan.
PURPOSE: To clarify the correlation between the radiation dose and clinical
outcome of sodium borocaptate-based intraoperative boron neutron capture
therapy in patients with malignant glioma. METHODS AND MATERIALS: The first
protocol (P1998, n = 8) prescribed a maximal gross tumor volume (GTV) dose
of 15 Gy. In 2001, a dose-escalated protocol was introduced (P2001, n = 11),
which prescribed a maximal vascular volume dose of 15 Gy or, alternatively,
a clinical target volume (CTV) dose of 18 Gy. RESULTS: The GTV and CTV doses
in P2001 were 1.1-1.3 times greater than those in P1998. The maximal
vascular volume dose of those with acute radiation injury was 15.8 Gy. The
mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and
16.5 Gy, respectively. A statistically significant correlation between the
GTV dose and median survival time was found. In the 11 glioblastoma patients
in P2001, the median survival time was 19.5 months and 1- and 2-year
survival rate was 60.6% and 37.9%, respectively. CONCLUSION: Dose escalation
contributed to the improvement in clinical outcome. To avoid radiation
injury, the maximal vascular volume dose should be <12 Gy. For long-term
survival in patients with glioblastoma after boron neutron capture therapy,
the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively.
PMID: 16750328 [PubMed - as supplied by publisher]
Abstract
-
| 5: Int
J Radiat Oncol Biol Phys. 2006 May 31; [Epub ahead of print] |
|
-
A phase II trial of accelerated radiotherapy using weekly
stereotactic conformal boost for supratentorial glioblastoma multiforme:
RTOG 0023.
Cardinale R, Won M, Choucair A, Gillin M, Chakravarti
A, Schultz C, Souhami L, Chen A, Pham H, Mehta
M.
Medical College of Virginia/Virginia Commonwealth University, Richmond, VA.
PURPOSE: This phase II trial was performed to assess the feasibility,
toxicity, and efficacy of dose-intense accelerated radiation therapy using
weekly fractionated stereotactic radiotherapy (FSRT) boost for patients with
glioblastoma multiforme (GBM). METHODS AND MATERIALS: Patients with
histologically confirmed GBM with postoperative enhancing tumor plus tumor
cavity diameter <60 mm were enrolled. A 50-Gy dose of standard radiation
therapy (RT) was given in daily 2-Gy fractions. In addition, patients
received four FSRT treatments, once weekly, during Weeks 3 to 6. FSRT dosing
of either 5 Gy or 7 Gy per fraction was given for a cumulative dose of 70 or
78 Gy in 29 (25 standard RT + 4 FSRT) treatments over 6 weeks. After the RT
course, carmustine (BCNU) at 80 mg/m(2) was given for 3 days, every 8 weeks,
for 6 cycles. RESULTS: A total of 76 patients were analyzed. Toxicity
included: 3 Grade 4 chemotherapy, 3 acute Grade 4 radiotherapy, and 1 Grade
3 late. The median survival time was 12.5 months. No survival difference is
seen when compared with the RTOG historical database. Patients with gross
total resection (41%) had a median survival time of 16.6 months vs. 12.0
months for historic controls with gross total resection (p = 0.14).
CONCLUSION: This first, multi-institutional FSRT boost trial for GBM was
feasible and well tolerated. There is no significant survival benefit using
this dose-intense RT regimen. Subset analysis revealed a trend toward
improved outcome for GTR patients suggesting that patients with minimal
disease burden may benefit from this form of accelerated RT.
PMID: 16750317 [PubMed - as supplied by publisher]
Abstract
-
| 6: J
Clin Oncol. 2006 May 20;24(15):2386-7. |
|
-
Metachronous intracranial germinoma in a patient with a
previous primary mediastinal seminoma.
Bedano PM, Bonnin J, Einhorn LH.
Publication Types:
PMID: 16710037 [PubMed - indexed for MEDLINE]
| 7: J
Neuropathol Exp Neurol. 2006 Mar;65(3):204-16. |
|
-
The burden of radiation-induced central nervous system
tumors: a single institution s experience.
Kleinschmidt-Demasters BK, Kang JS, Lillehei KO.
Department of Neurosurgery, University of Colorado Health Sciences Center,
Denver, 80262, USA. BK.DeMaster@uchsc.edu
Radiation-induced tumors of the central and peripheral nervous systems are
becoming a noticeable subset of tumors seen at referral institutions. This
paper outlines a single institution s experience with 22 examples of
secondary meningiomas, gliomas, and sarcomas that developed in adults. These
tumors are being increasingly encountered by physicians, but the greatest
burden is on the patients themselves, who not only experience the
life-altering effects of the original tumor and the subsequent delayed
cognitive effects of radiotherapy, but later develop a second intracranial
neoplasm. We detail a particularly poignant example of a 34-year-old man who
developed a high-grade sarcoma with rhabdomyosarcomatous and osteogenic
elements. Local control was difficult over the next year, and he eventually
developed cerebrospinal fluid dissemination and succumbed. Although
radiation-induced neoplasm remain relatively infrequent numerically, each
case reminds us of the need for new, less toxic, and more targeted therapies
for brain neoplasms.
Publication Types:
PMID: 16651882 [PubMed - indexed for MEDLINE]
Abstract
-
| 8: JAMA.
2006 Jun 7;295(21):2535-6. |
|
-
Radiosurgery and whole-brain radiation therapy for brain
metastases: either or both as the optimal treatment.
Raizer J.
Publication Types:
PMID: 16757726 [PubMed - in process]
-
| 9: JAMA.
2006 Jun 7;295(21):2483-91. |
|
-
Stereotactic radiosurgery plus whole-brain radiation
therapy vs stereotactic radiosurgery alone for treatment of brain
metastases: a randomized controlled trial.
Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda
T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura
H, Kunieda E, Inomata T, Hayakawa K, Katoh N,
Kobashi G.
Departments of Radiology, Hokkaido University Graduate School of Medicine,
Sapporo, Japan. h-aoyama@umin.ac.jp
CONTEXT: In patients with brain metastases, it is unclear whether adding
up-front whole-brain radiation therapy (WBRT) to stereotactic radiosurgery
(SRS) has beneficial effects on mortality or neurologic function compared
with SRS alone. OBJECTIVE: To determine if WBRT combined with SRS results in
improvements in survival, brain tumor control, functional preservation rate,
and frequency of neurologic death. DESIGN, SETTING, AND PATIENTS: Randomized
controlled trial of 132 patients with 1 to 4 brain metastases, each less
than 3 cm in diameter, enrolled at 11 hospitals in Japan between October
1999 and December 2003. INTERVENTIONS: Patients were randomly assigned to
receive WBRT plus SRS (65 patients) or SRS alone (67 patients). MAIN OUTCOME
MEASURES: The primary end point was overall survival; secondary end points
were brain tumor recurrence, salvage brain treatment, functional
preservation, toxic effects of radiation, and cause of death. RESULTS: The
median survival time and the 1-year actuarial survival rate were 7.5 months
and 38.5% (95% confidence interval, 26.7%-50.3%) in the WBRT + SRS group and
8.0 months and 28.4% (95% confidence interval, 17.6%-39.2%) for SRS alone (P
= .42). The 12-month brain tumor recurrence rate was 46.8% in the WBRT + SRS
group and 76.4% for SRS alone group (P<.001). Salvage brain treatment was
less frequently required in the WBRT + SRS group (n = 10) than with SRS
alone (n = 29) (P<.001). Death was attributed to neurologic causes in
22.8% of patients in the WBRT + SRS group and in 19.3% of those treated with
SRS alone (P = .64). There were no significant differences in systemic and
neurologic functional preservation and toxic effects of radiation.
CONCLUSIONS: Compared with SRS alone, the use of WBRT plus SRS did not
improve survival for patients with 1 to 4 brain metastases, but intracranial
relapse occurred considerably more frequently in those who did not receive
WBRT. Consequently, salvage treatment is frequently required when up-front
WBRT is not used. TRIAL REGISTRATION: umin.ac.jp/ctr Identifier: C000000412.
PMID: 16757720 [PubMed - in process]
-
| 10: Neurology. 2006 Apr
25;66(8):1287; author reply 1287. |
|
-
Comment on:
- Neurology. 2005 Oct 11;65(7):1129-31.
Primary central nervous system lymphomas (PCNSL): MRI
response criteria revised.
Schlegel U, Jurgens A, Pels H.
Publication Types:
PMID: 16636266 [PubMed - indexed for MEDLINE]
-
| 11: Neurology. 2006 Apr
25;66(8):1279-80. |
|
-
Differential effects of left and right hemispheric
seizure onset on heart rate.
Kawai M, Goldsmith IL, Verma A.
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
Publication Types:
PMID: 16636257 [PubMed - indexed for MEDLINE]
-
| 12: Neurology. 2006 Apr
25;66(8):1261-3. |
|
-
Nonconvulsive status epilepticus in metastatic CNS
disease.
Blitshteyn S, Jaeckle KA.
Department of Neurology, Mayo Clinic, Jacksonville, FL 3222, USA.
The authors describe the clinical and diagnostic characteristics of four
patients with metastatic CNS disease presenting in de novo nonconvulsive
status epilepticus (NCSE). Treatment with anticonvulsants resulted in
resolution of NCSE in two patients and a brief improvement in mental status
in the other two patients. NCSE should be considered in the differential
diagnosis of acute mental status change in patients with metastatic CNS
disease.
Publication Types:
PMID: 16636249 [PubMed - indexed for MEDLINE]
-
| 13: Neurology. 2006 Apr
25;66(8):E27. |
|
-
Ocular neuromyotonia: video case report.
Morris EB 3rd, Gajjar A, Hoehn ME.
brannon.morris@stjude.org
Publication Types:
PMID: 16636223 [PubMed - indexed for MEDLINE]
-
| 14: Neuroradiology. 2006
Jun 3; [Epub ahead of print] |
|
-
Multiparametric 3T MR approach to the assessment of
cerebral gliomas: tumor extent and malignancy.
Di Costanzo A, Scarabino T, Trojsi F, Giannatempo GM,
Popolizio T, Catapano D, Bonavita S, Maggialetti N,
Tosetti M, Salvolini U, d'Angelo VA, Tedeschi G.
Department of Health Sciences, University of Molise, Via de Sanctis 2,
86100, Campobasso, Italy, alfonso.dicostanzo@unimol.it.
INTRODUCTION: Contrast-enhanced MR imaging is the method of choice for
routine assessment of brain tumors, but it has limited sensitivity and
specificity. We verified if the addition of metabolic, diffusion and
hemodynamic information improved the definition of glioma extent and grade.
METHODS: Thirty-one patients with cerebral gliomas (21 high- and 10
low-grade) underwent conventional MR imaging, proton MR spectroscopic
imaging ((1)H-MRSI), diffusion weighted imaging (DWI) and perfusion weighted
imaging (PWI) at 3 Tesla, before undergoing surgery and histological
confirmation. Normalized metabolite signals, including choline (Cho), N-acetylaspartate
(NAA), creatine and lactate/lipids, were obtained by (1)H-MRSI; apparent
diffusion coefficient (ADC) by DWI; and relative cerebral blood volume (rCBV)
by PWI. RESULTS: Perienhancing areas with abnormal MR signal showed 3
multiparametric patterns: "tumor", with abnormal Cho/NAA ratio,
lower ADC and higher rCBV; "edema", with normal Cho/NAA ratio,
higher ADC and lower rCBV; and "tumor/edema", with abnormal Cho/NAA
ratio and intermediate ADC and rCBV. Perienhancing areas with normal MR
signal showed 2 multiparametric patterns: "infiltrated", with high
Cho and/or abnormal Cho/NAA ratio; and "normal", with normal
spectra. Stepwise discriminant analysis showed that the better
classification accuracy of perienhancing areas was achieved when regarding
all MR variables, while (1)H-MRSI variables and rCBV better differentiated
high- from low-grade gliomas. CONCLUSION: Multiparametric MR assessment of
gliomas, based on (1)H-MRSI, PWI and DWI, discriminates infiltrating tumor
from surrounding vasogenic edema or normal tissues, and high- from low-grade
gliomas. This approach may provide useful information for guiding
stereotactic biopsies, surgical resection and radiation treatment.
PMID: 16752135 [PubMed - as supplied by publisher]
Abstract
-
| 15: Neurosurgery. 2006
Apr;58(4 Suppl 2):ONS-327-36; discussion ONS-336-7. |
|
-
Combined anterior and anterolateral approaches to the
cranial base: complication analysis, avoidance, and management.
Origitano TC, Petruzzelli GJ, Leonetti JP, Vandevender
D.
Department of Neurological Surgery, Loyola Center for Cranial Base Surgery,
Loyola Stritch School of Medicine, Loyola University Medical Center,
Maywood, Illinois 60153, USA. torigit@lumc.edu
OBJECTIVE: During the past decade, applications of anterior and
anterolateral cranial approaches for both benign and malignant pathologies
have expanded in frequency and application. Complications associated with
these procedures impact significantly on patient outcome. The primary aim of
this study is to detail the strategies for complication management and
avoidance developed from experience with 120 patients who underwent anterior
and anterolateral cranial base procedures during the past 14 years. METHODS:
Between July 1990 and February 2004, 62 male and 58 female patients
underwent 120 combined (neurological surgery and otolaryngology joint
participation) anterior and anterolateral cranial base procedures.
Fifty-four percent had malignant pathology, and 46% had benign pathology.
The approaches taken were transfacial (10%), extended subfrontal (33%),
lateral craniofacial (23%), and anterior craniofacial (35%). Thirty-day
morbidity and mortality were analyzed. RESULTS: Twenty (17%) patients
experienced at least one complication. Malignancy and reoperation,
regardless of histology, appeared to affect the complication rate. A decline
in complications occurred with experience, in part because of changes in
management that reflected the complication experience (25% in Patients 0-31,
18% in Patients 32-70, 10% in Patients 71-120). Methodology is detailed for
avoidance and management of retraction injury, infection, tension
pneumocephalus, cerebrospinal fluid leak, pericranial flap failure, free
flap sizing, dural banding, intracranial hypotension, and cerebrovascular
events. Individual patient analysis, complications timing, and strategy for
management are discussed. CONCLUSION: Improved patient outcomes for anterior
and anterolateral cranial base surgery are, in part, directly related to the
ability to avoid and manage associated complications. Experience, avoidance,
and interdiction are key factors in complication management.
Publication Types:
PMID: 16582657 [PubMed - indexed for MEDLINE]
-
| 16: Neurosurgery. 2006
Apr;58(4 Suppl 2):ONS-292-303; discussion ONS-303-4. |
|
-
Implementation of fiber tract navigation.
Nimsky C, Ganslandt O, Fahlbusch R.
Department of Neurosurgery, University Erlangen-Nurnberg, Erlangen, Germany.
nimsky@nch.imed.uni-erlangen.de
OBJECTIVE: To implement fiber tracking in a common neuronavigation
environment for routine clinical use to visualize major white matter tracts
intraoperatively. METHODS: A single-shot, spin-echo diffusion weighted echo
planar imaging sequence with six diffusion directions on a 1.5 T magnetic
resonance scanner was used for diffusion tensor imaging. For
three-dimensional (3-D) tractography, we applied a knowledge-based multiple
volume of interest approach. Tracking was initiated in each voxel of the
initial seed volume in retrograde and orthograde directions according to the
direction of the major eigenvector by applying a tensor deflection
algorithm. Tractography results were displayed as streamlines assigned
direction encoding color. After selecting the fiber tract bundle of interest
by defining inclusion and exclusion volumes, a 3-D object was generated
automatically by wrapping the whole fiber tract bundle. This 3-D object was
displayed along with other contours representing tumor outline and further
functional data with the microscope heads-up display. RESULTS: In 16
patients (three cavernomas, 13 gliomas), major white matter tracts
(pyramidal tract, n = 14; optic radiation, n = 2) were visualized
intraoperatively with a standard navigation system. Three patients developed
a postoperative paresis, which resolved in two in the postoperative course.
Additional planning time for tractography amounted to up to 10 minutes.
Comparing the tractography results with a fiber bundle generated on a
different platform by applying a distortion-free sequence revealed a good
congruency of the defined 3-D outlines in the area of interest. CONCLUSION:
Fiber tract data can be reliably integrated into a standard neuronavigation
system, allowing for intraoperative visualization and localization of major
white matter tracts such as the pyramidal tract or optic radiation.
Publication Types:
PMID: 16582653 [PubMed - indexed for MEDLINE]
-
| 17: Oncogene. 2006 Jun 5; [Epub
ahead of print] |
|
-
Ku80 and p53 suppress medulloblastoma that arise
independent of Rag-1-induced DSBs.
Holcomb VB, Vogel H, Marple T, Kornegay RW, Hasty
P.
1The Department of Molecular Medicine, The University of Texas Health
Science Center at San Antonio, The Institute of Biotechnology, San Antonio,
TX, USA.
Ku80 maintains the genome by repairing DNA double-strand breaks (DSBs)
through nonhomologous end joining (NHEJ), a pathway that repairs nonspecific
DSBs and Rag-1 Rag-2 (Rag)-specific DSBs. As a result, Ku80 deletion results
in phenotypes characteristic of defective repair for both nonspecific DSBs
(gamma-radiation hypersensitivity and genomic instability) and Rag-specific
DSBs (immunodeficiency). ku80(-/-) mice also exhibit neuronal apoptosis, but
we do not know the type of DSBs responsible for this response. In spite of
genomic instability and immunodeficiency, cancer incidence is not increased
in ku80(-/-) mice. However, deletion of the tumor suppressor, p53 greatly
increases pro-B-cell lymphoma in ku80(-/-) mice due to IgH/c-Myc
translocations suggesting that responses to Rag-specific DNA DSBs suppress
cancer. Like suppression of pro-B-cell lymphoma, neuronal apoptosis requires
p53 presenting the intriguing possibility that Rag-specific DSBs mediate
neuronal development as they do lymphocyte development. Here we delete Rag-1
from ku80(-/-)p53(-/-) mice to differentiate the impact nonspecific vs
Rag-specific DSBs have on ku80(-/-) mice. We find that deleting Rag-1
prevents pro-B cell lymphoma confirming Rag-induced DSBs induce this form of
cancer. Both the triple mutant mice and the p53(-/-)rag-1(-/-) mice exhibit
T-cell lymphoma and medulloblastoma; incidence of T-cell lymphoma is the
same for both cohorts whereas incidence of medulloblastoma is higher for the
triple-mutant cohort. Thus, p53-mediated neuronal apoptosis likely
suppresses medulloblastoma in Ku80-deleted mice and Ku80 likely suppresses
medulloblastoma by repairing nonspecific DNA DSBs instead of Rag-specific
DSBs. Our observations are the first to show that Ku80 suppresses cancer
caused by nonspecific DNA damage and we present a novel mouse model for
medulloblastoma.Oncogene advance online publication, 5 June 2006;
doi:10.1038/sj.onc.1209704.
PMID: 16751807 [PubMed - as supplied by publisher]
Abstract
-
| 18: Radiology. 2006
Jun;239(3):650-64. |
|
-
Intracranial cysts: radiologic-pathologic correlation and
imaging approach.
Osborn AG, Preece MT.
Department of Radiology, University of Utah Medical Center, Salt Lake City,
Utah 84103, USA.
Cysts and cystic-appearing intracranial masses have a broad imaging and
pathologic spectra. The authors review the pathologic findings, origin,
radiologic appearance, and differential diagnosis of many different
intracranial cysts. A diagnostic algorithm based on most common anatomic
locations is presented that helps narrow the differential diagnosis.
Publication Types:
PMID: 16714456 [PubMed - indexed for MEDLINE]
-
| 19: BMC
Cancer. 2006 Jun 7;6(1):152 [Epub ahead of print] |
|
-
Hormonal exposures and the risk of intracranial
meningioma in women: A population-based case-control study.
Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD,
van Belle G.
ABSTRACT: BACKGROUND: The role of exogenous hormone exposures in the
development of meningioma is unclear, but these exposures have been proposed
as one hypothesis to explain the over-abundance of such tumors in women.
METHODS: The association between oral contraception (OC) or hormone
replacement therapy (HRT) and intracranial meningioma in women was
investigated using a population-based, matched case-control study. Exposures
for 143 cases and 286 controls matched on age within five years were
obtained by interview. Diagnoses were confirmed histopathologically and
estrogen and progesterone receptor assays conducted. RESULTS: Although risk
of meningioma appeared modestly elevated in past OC users (OR = 1.5, 95% CI
0.8 - 2.7), and in current users (OR = 2.5, 95% CI 0.5 - 12.6), the
confidence intervals were wide. No significant association between
meningioma risk and duration of OC use was found. Likewise, risk of
meningioma was only weakly associated with past use of HRT (OR = 0.7, 95% CI
0.4 - 1.3), and not at all with current use of HRT (OR = 1.0, 95% CI 0.5 -
2.2). Of 142 available specimens, 2 (1%) expressed estrogen receptors,
whereas 130 (92%) expressed progesterone receptors (PR). OC use was
associated with increased risk of a meningioma expressing less rather than
more PR (OR = 3.2, 95% CI 1.3 - 8.0). Overall, in post menopausal women, HRT
use appeared to confer a non-significant protective effect, and was not
associated with low or high PR expressing meningiomas. CONCLUSIONS: This
study found little evidence of associations between meningioma and exogenous
hormone exposures in women but did suggest that some hormonal exposures may
influence tumor biology in those women who develop meningioma.
PMID: 16759391 [PubMed - as supplied by publisher]
Abstract
|  Reprint
-
| 20: BMC
Cancer. 2006 Jun 3;6(1):148 [Epub ahead of print] |
|
-
Inverse association of antioxidant and phytoestrogen
nutrient intake with adult glioma in the San Francisco Bay Area: a
case-control study.
Tedeschi-Blok N, Lee M, Sison JD, Miike R, Wrensch
M.
ABSTRACT: BACKGROUND: Increasing evidence from epidemiologic studies suggest
that oxidative stress may play a role in adult glioma. In addition to
dietary antioxidants, antioxidant and weak estrogenic properties of dietary
phytoestrogens may attenuate oxidative stress. Our hypothesis is that
long-term consumption of dietary antioxidants and phytoestrogens such as
genistein, daidzein, biochanin A, formononetin, matairesinol,
secoisolariciresinol and coumestrol, may reduce the risk of adult glioma.
METHODS: Using unconditional logistic regression models, we compared
quartiles of consumption for several specific antioxidants and
phytoestrogens among 802 adult glioma cases and 846 controls from two study
series from the San Francisco Bay Area Adult Glioma Study, 1991 - 2000,
controlling for vitamin supplement usage, age, socioeconomic status, gender,
ethnicity and total daily calories. For cases, dietary information was
either self-reported or reported by a proxy. For controls, dietary
information was self-reported. Gender- and series- specific quartiles of
average daily nutrient intake, estimated from food-frequency questionnaires,
were computed from controls. RESULTS: Significant p-values (trend test) were
evaluated using significance levels of either 0.05 or 0.003 (the Bonferroni
corrected significance level equivalent to 0.05 adjusting for 16
comparisons). For all cases compared to controls, statistically significant
inverse associations were observed for antioxidant index (p<0.003),
carotenoids (alpha- and beta-carotene combined, p<0.05), daidzein
(p=0.003), matairesinol (p<0.05), secoisolariciresinol (p<0.003), and
coumestrol (p<0.003). For self-reported cases compared to controls,
statistically significant inverse associations were observed for antioxidant
index (p<0.05) and daidzein (p<0.05). CONCLUSIONS: Our results support
inverse associations of glioma with higher dietary antioxidant index and
with higher intake of certain phytoestrogens, especially daidzein.
PMID: 16749939 [PubMed - as supplied by publisher]
Abstract
| Reprint
-
|
Volume 5, Number 24 - 12 June 2006